|
Originally published In Press as doi:10.1074/jbc.R000004200 on May 4, 2000
J. Biol. Chem., Vol. 275, Issue 31, 23409-23412, August 4, 2000
MINIREVIEW
The Leukocyte Integrins*
Estelle S.
Harris §,
Thomas M.
McIntyre §¶,
Stephen M.
Prescott **, and
Guy A.
Zimmerman §
From the § Program in Human Molecular Biology and
Genetics, Eccles Institute of Human Genetics, ** Huntsman Cancer
Institute, and Departments of Internal Medicine,
Oncologic Sciences, and ¶ Pathology, University of
Utah, Salt Lake City, Utah 84112
 |
Integrins on Leukocytes |
Leukocytes are marrow-derived cells of
diverse form and function that circulate in the blood in a quiescent
state of low adhesiveness before migrating into tissues to defend
against invading microbes, participate in immune functions and wound
repair, or become fixed extracellular residents. Some, such as
T-lymphocytes, recirculate and traverse blood, organ, and lymphatic
compartments during long cycles of immune surveillance. Others, notably
polymorphonuclear leukocytes
(PMNs,1 neutrophils), are
rapid response cells specialized for acute spatially targeted defensive
actions that can be mounted in minutes. Leukocytes are also effectors
of pathologic inflammation when their accumulation and actions are
disregulated. Integrins on their surfaces, together with other plasma
membrane adhesion molecules, are required for interactions of
leukocytes with endothelial cells and other cell types and with matrix
structures (1).2 The
functional state, density, and topography of integrins on leukocytes
are regulated by lipid, cytokine, and chemokine signaling molecules and
by "cross-talk" from other surface adhesion molecules (1-6).
Each class of leukocytes displays a particular pattern of integrins
that can change in a signal- and time-dependent fashion. For example, resting human T lymphocytes (T cells) express
1, 2, and 7 integrins, but
this varies with the subclass and is altered by immune stimulation (5).
Freshly isolated human monocytes express 1 and
2 integrins, but their culture and/or differentiation into macrophages changes the pattern and induces
v 3 (5, 7). Human PMNs, once thought to
express only 2 integrins, display 1 and
3 heterodimers and use them in motility and migration (8-12). A common feature, however, is that each leukocyte subtype expresses one or more members of the 2 integrin family.
Further, the 2 heterodimers are restricted to cells of
the leukocyte lineage. The remainder of this minireview will focus on
the structure and function of the 2 or "leukocyte"
integrins, which were among the first adhesion molecules to be studied
at the molecular level. The most recently identified member of the
subfamily,
D 2,3
is still being characterized (13-16).
 |
Structure and Distribution |
The gene for the 2 chain
(Mr 95,000) is located in band q22 on human
chromosome 21 and encodes a cysteine-rich transmembrane protein with
six N-linked extracellular glycosylation sites. The cytoplasmic tail contains sequences critical for inside-out signaling and cytoskeletal association. Cytoplasmic residues are differentially phosphorylated in an agonist-dependent fashion in
neutrophils, but the effect on adhesive function is not clear. Each of
56 cysteine residues in 2, including four repeated
cysteine motifs, is conserved in the 1,
2, and 3 integrin chains and may be
important for a rigid tertiary structure. The extracellular portion of
2 contains a 241-amino acid "I-like" domain near the
N terminus (Fig. 1) that is highly
conserved in other subunits and is critical for ligand recognition
(17, 18) (see below).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 1.
Features of
2 integrins. The 
heterodimeric structure is common to all integrins. The chain
includes seven extracellular N-terminal homologous repeats organized
into a propeller structure. The chain I domain is shown in
pink with the embedded MIDAS motif in orange, and
the chain I-like domain with MIDAS motif is shown in corresponding
fashion. The GFFKR sequence (green) in the cytoplasmic tail
of the subunit is involved in heterodimer assembly and regulation
of ligand recognition. The heterodimer is illustrated in the
"closed" or inactive state that undergoes tertiary and quaternary
changes in response to inside-out signals. See "Structure and
Distribution," "Ligand Recognition," and "Inside-out
Signaling" for details.
|
|
The genes for human L (Mr
177,000), M (Mr 165,000),
X (Mr 150,000), and
D (Mr 160,000) are located in a
cluster on chromosome 16 (19). Their sequences are similar with
M, X, and D having 60-66% amino acid identity and sharing 35% identity with
L. Each contains a distal N-terminal extracellular "I
domain" (signifying "inserted" or "interactive"; also called
the "A domain" because of homology to the A motif in von Willebrand
factor) of approximately 200 amino acids that is critical for ligand
binding (17, 20). I domains are also present in 1,
2, and E. The N-terminal extracellular regions of the subunits include seven repeats that fold into a propeller configuration. The I domains lie within the third repeat
(Fig. 1) and are predicted to be exposed and mobile. The three
membrane-proximal N-terminal repeats resemble EF hand
Ca2+-binding motifs and are situated on the lower face of
the propeller away from the ligand contact sites, where they may
contribute to orientation of the propeller and/or to interaction with
the 2 subunit (20).
The cytoplasmic tails of the chains are constitutively
phosphorylated in some leukocyte types, but the contribution of
phosphorylation to function is unclear (1). The membrane-proximal
cytoplasmic domains of each chain contain a GFFKR motif common to
all integrin subunits that putatively serves as a "hinge" that
locks the heterodimers into a low affinity conformation in the absence
of activating signals and is involved in / subunit association (21).
The factors that dictate leukocyte-specific expression of the and chains remain incompletely defined (1). In myeloid leukocyte
subtypes, specific 2 heterodimers are differentially targeted to subcellular storage granules in addition to the plasma membrane. Cellular activation then leads to translocation of granular 2 heterodimers to the surface. Activation of
constitutive surface 2 integrins can occur without
translocation of additional heterodimers from granules; treatment of
neutrophils with ceramide or cytochalasins dissociates these two events
(1, 4).4 There is
differential activation of constitutive surface and newly translocated
2 integrins on migrating PMNs and redistribution of
heterodimers to specialized regions of the plasma membrane (1, 22).
2 integrins dynamically associate with other plasma membrane proteins. These interactions alter adhesive and signaling functions (1) (see the last minireview in this series by Woods and
Couchman (83)).
 |
Ligands |
Each of the 2 integrins recognizes one or more
members of the intercellular adhesion molecule (ICAM) family.
M 2, X 2, and
D 2 also recognize proteins of other
classes and (in the case of M 2 and
X 2) polysaccharides. The unifying feature
of protein ligands may be the presence of acidic residues (aspartate or
glutamate) positioned in flexible loops that allow them to coordinate
Mg2+ or Mn2+ and form a bridge to the I and/or
I-like domains on the integrin heterodimer (17). The RGD motif, which
is a critical feature in many integrin ligands, is not a required
feature in ligands for 2 heterodimers.
 |
Ligand Recognition |
The crystal structures of the I domains of M and
L have been solved (17, 23), providing rosetta stones
for general understanding of integrin structure-function relationships.
The crystal structure of the I domain of M reveals a
coordination locus for Mg2+ and Mn2+ that is
proposed as a general "metal ion-dependent adhesion
site" (MIDAS) consisting of the sequence DXSXS
together with downstream non-contiguous Asp and Thr residues (17, 24)
(Fig. 1). Blocking and mutagenesis of the metal coordinating sites in
the MIDAS motifs of subunits alter or abolish ligand binding, as
does mutagenesis of key residues in the flanking regions.2
A DXSXS motif is also found in the I-like domain
of the 2 subunit. Its mutation eliminates ligand
recognition (17, 18, 25).
Changes in tertiary conformation of the I domains may be a general
mechanism that dictates active and inactive states of the
2 integrins (1). The crystal I domain of
M assumes two conformations, an open or "active" and
a closed or "inactive" structure, that differentially recognize
ligands although conformational alterations were not seen when crystals
of the I domain of L were grown under various ionic
conditions (23, 26, 27). Quaternary structural alterations likely also
occur. One model proposes that the subunit I-like domain folds over
the subunit propeller in the low affinity unactivated state,
blocking the I domain and its central MIDAS motif (Fig. 1).
Quaternary changes triggered by inside-out signals (see below) shift
the chain I-like domain, exposing the subunit I domain and
other ligand recognition sites in the propeller in concert with
simultaneous conversion of the subunit I domain to an active
conformation via tertiary changes (28).
Thus, dynamic structural alterations in 2 heterodimers
are involved in ligand recognition, as with other classes of integrins
(see the first minireview in this series by Plow et al.
(84)). Modulation of avidity is also involved (see below).
 |
Inside-out Signaling |
Activation of leukocytes by agonists that bind to diverse classes
of receptors triggers ligand recognition by 2 integrins. This process is termed "inside-out signaling," integrin
"activation," and "functional up-regulation" (1). Rapid,
regulated modulation of ligand recognition is critical for leukocytes,
because they must circulate in a non-adhesive state before targeting
and arrest at specific sites. The molecular mechanisms that mediate
inside-out signaling of integrins have been elusive (see the second
minireview in this series by Ginsburg and co-workers (85)). More than
one pathway may trigger inside-out signaling of an individual
2 integrin heterodimer (29, 30). Transfected and mutated
cell systems are now popular for analysis of integrin signaling
(30-32). Such models suggest that inside-out signaling of
2 integrins occurs via mechanisms dependent on the small
GTPase Rho (33, 34) and that there is differential intracellular
regulation of the activity of 2 versus
1, 3, and 7 integrins in
the same transfected cell type (35-37). There are cell-specific
aspects of integrin regulation, however, that may operate in model cell
systems but not in primary leukocytes and vice versa (38).
Analysis of inside-out signaling of 2 integrins is most
detailed for L 2. Changes in both affinity
and avidity are involved, depending in part on the cellular system and
the stimulus chosen to alter its adhesive function. Low and high
affinity states of L 2 occur on
lymphocytes (39) and other leukocytes (1). Manipulation of the
"extracellular face" of L 2 using
divalent cations and function-perturbing antibodies induces rapid
dynamic changes in recognition of ICAM-1 and other ligands (1, 40). Recent experiments with soluble recombinant peptides based on the I
domain of L indicate that this region is required for
ICAM-1 recognition when L 2 shifts to the
high affinity state on cultured T cells treated with Mg2+
(41). In contrast, treatment of T cells with phorbol esters or agents
that increase intracellular Ca2+ causes clustering of
L 2 and increased avidity of binding
without detectable change in affinity (41-44). Lateral motion of
L 2 in the plasma membranes of
Epstein-Barr virus-transformed lymphoblasts is enhanced by phorbol
esters and by cytochalasins, suggesting that conversion from the
non-adhesive to the adhesive state involves signals that alter
cytoskeletal interactions and allow the integrin to segregate into
clusters or adhesive patches (45). Clustering of membrane "rafts"
containing L 2 occurs in murine thymocytes and activated T cells and confers adhesion to ICAM-1 (46). There is
additional evidence for avidity modulation of
L 2 in surrogate cell models (47, 48).
Lateral segregation of L 2 in the plane of
contact occurs in T cells adherent to cellular targets or purified proteins in model membranes (49, 50). Differential regulation of
affinity versus avidity of L 2
is triggered by specific signals and may involve a two-step mechanism
in which increased affinity, which can be induced by ICAM-1 and
potentially by other binding partners, and altered avidity occur in
sequence (41, 48).
Truncations, mutations, and deletions of the GFFKR motif of
L (Fig. 1) in a Jurkat T cell line and in K562
transfectants cause constitutive ICAM-1 recognition; there is also
additional evidence that the membrane-proximal region of the cytoplasmic tail exerts a general inhibitory effect on ligand
recognition that is independent of the chain (1, 21, 30, 51). The 2 cytoplasmic tail is, however, critical for modulation
of L 2 adhesiveness (1, 38, 47, 51). The
2 chain associates with a variety of cytoskeletal and
regulatory proteins, including -actinin, talin, filamin, vinculin,
and Rack 1. Certain of these interactions have been demonstrated to be
altered when leukocytes of different classes are activated by
physiologically relevant stimuli and to regulate
L 2 function (1, 52). Inside-out signaling
of L 2 on B lymphoblastoid cells is
regulated by Rho acting downstream of protein kinase C (PKC) (53),
consistent with studies in transfected cells mentioned
above.5
A member of the Sec7 family, cytohesin-1, modulates
L 2 in lymphocytic and monocytic cell
lines (35, 54-56). Cytohesin-1 was identified using the intracellular
domain of 2 in a yeast two-hybrid screen; it has a
C-terminal pleckstrin homology (PH) domain and an N-terminal motif
similar to the yeast Sec7 domain, conferring membrane association and
guanine nucleotide exchange factor activity (35, 54). Cytohesin-1
weakly coimmunoprecipitated with L 2 in
lysates of a Jurkat T cell line, but not with
4 1 (35). Overexpression of cytohesin-1 or
its Sec7 motif in Jurkat cells induced
L 2-dependent adhesion to
immobilized ICAM-1 without increasing L 2
heterodimers on the surface, whereas overexpression of the PH domain
inhibited adhesion stimulated by T cell receptor engagement (35).
Expression of a constitutively active chimeric phosphatidylinositol
3-kinase (PI 3-kinase) induced adhesion of Jurkat cells to ICAM-1 and
increased membrane association of cytohesin-1, both of which were
inhibited by overexpression of the PH domain but not by a control PH
motif (54). This suggests that PI 3-kinase regulates recruitment of
cytohesin-1 to the plasma membrane utilizing the PH domain where it
mediates inside-out signaling of L 2, potentially via the Sec7 domain (54, 56). Additional evidence in other
systems indicates that signals delivered via PI 3-kinases activate
integrins, potentially converging with signals from PKC.2,5
It is unknown if inside-out signaling of
L 2 on primary leukocytes is mediated by
PI 3-kinase-dependent cytohesin-1 translocation. A recently
identified factor that is structurally similar to cytohesin-1, GRP1,
also regulates L 2 in leukocyte cell lines
(57).
Inside-out signaling and ligand recognition of
M 2 follows paradigms outlined for
L 2 (1, 26-29). Two functional states of
the crystallized M I domain indicate a basis for changes
in conformation (17, 26, 27). Avidity modulation involving clustering
of M 2 or cell spreading also occurs (1,
29, 30, 58). L-plastin, an actin-organizing protein, regulates M 2 on human monocytes and neutrophils
based on experiments with cell-permeant peptides (59). In human
neutrophils, inside-out signaling of M 2
was dependent on PI 3-kinase and actin cytoskeletal reorganization when
triggered by engagement of Fc receptors but not when the leukocytes
were activated through the receptors for inflammatory peptides (29). An
inhibitor of PI 3-kinase also failed to block
M 2-dependent adhesive
interactions of neutrophils in earlier experiments (60). These findings
are consistent with differential regulation of
M 2 and L 2
via the cytoplasmic tails (30) and also suggest alternative
mechanisms for signaling of cytohesin-1 interaction with the
cytoplasmic tail of 2 if it is central to activation of
M 2, as proposed for
L 2 (see above). Pak1, a serine/threonine
kinase, may be an intermediary in a pathway leading to inside-out
signaling of M 2 in neutrophils (29).
 |
Outside-in Signaling |
Engagement of integrins delivers outside-in signals that
trigger intracellular transduction cascades, in addition to mediating adhesion. These outside-in signals can also be integrated with signals
delivered through receptors for signaling molecules to yield
coordinated functional responses. Cross-linking of leukocyte integrins
with antibodies against 2 or specific subunits,
engagement of 2 heterodimers with specific ligands, or
coengagement of 2 integrins together with other surface
structures or receptors delivers outside-in signals that lead to
diverse cellular responses (1).2 Signaling to gene
regulatory pathways involves transcriptional events and mRNA
stabilization and is differentially affected by experimental conditions
when 1 versus 2 integrins are
engaged (61-64). Outside-in signaling by specific 2
integrins may vary in leukocyte subtypes (65) and is impaired in
leukocytes from subjects with leukocyte adhesion deficiency type I (LAD
I) (see below) (66, 67).
Several intracellular signaling pathways are triggered by engagement of
2 integrins (1). Activation of focal adhesion kinase
(FAK) is central to many paradigms of outside-in signaling by
integrins, and FAK binds peptides based on the sequence of the
2 cytoplasmic domain in addition to 1 and
3 cytoplasmic peptides (68). Nevertheless, FAK does not
appear to be critical for outside-in signaling by 2
integrins, and it is inconsistently detected in human monocytes and
neutrophils (63, 69) even though phosphorylation on tyrosine occurs in
these cells in response to 2 integrin engagement (1,
67). In contrast, the human THP-1 monocytic leukemia cell does express
FAK (70), illustrating the potential differences in integrin signaling
in primary leukocytes versus transformed cell lines.
Integrin-linked kinase, a serine/threonine kinase that associates with
1 cytoplasmic domains, and calreticulin, which
associates with the GFFKR sequence of subunits, mediate signaling
functions of integrins (71, 72), but it is not known if they regulate 2 heterodimers.
 |
Genetically Altered Animal Models |
Mice with partial (73) and complete (74) deficiency of
2 integrins and specific deletions of
L 2 (75), M 2
(76, 77), and
D 26
have been produced. Animals deficient in all 2 integrins
display phenotypic features of humans with LAD I (see below) including neutrophilia and a defect in accumulation of PMNs in inflamed skin. PMN
emigration into lung alveoli in response to a bacterial challenge and
into the peritoneum in response to a sterile irritant are preserved
(74). Blocking antibodies against 2 integrins inhibit
neutrophil accumulation under the same or similar conditions (1, 74),
however, suggesting alternative adhesion mechanisms that compensate for
deficiency of 2 integrins in mice. In contrast, absence
of PMNs from inflamed or injured extravascular sites is the usual
outcome in most humans with 2 integrin deficiency
(1).
Individual knockouts of L 2 and
M 2 yielded surprises, including the fact
that PMNs efficiently use L 2 for
emigration in mice null for M 2 (77). This
was unexpected, because the diversity of ligands recognized by
M 2 relative to
L 2 (1) suggested that it would be
required for traversing complex tissue compartments. Integrins
X 2 and/or
D 2 may substitute for
M 2, together with 1
integrins (1, 8-16). In inflammatory disease models neutrophil
effector functions are impaired in mice lacking M 2 (77, 78), potentially because of
absent outside-in signaling or deficient signal integration (see
above). One of these models indicated interaction between
M 2 and Fc receptors (78), which was
predicted by earlier in vitro observations (1). The same strain of mice was deficient in tissue mast cells, indicating that
M 2 is important in targeting and/or
development of this extravascular leukocyte subtype (79).
 |
LAD I and LAD I Variant Syndromes |
Humans with LAD I have absent or a greatly reduced display of all
2 integrin heterodimers on the surfaces of their
leukocytes, absent or dramatically reduced accumulation of PMNs and
monocytes at extravascular sites, recurrent life-threatening bacterial
infections, and impaired tissue remodeling and wound healing. Cells
from these subjects have defective adhesive and signaling functions
when studied in vitro (1, 2, 66, 67). The search for the molecular basis of LAD I led to identification and initial
characterization of 2 integrins (1). The syndrome
results from a variety of mutations that prevent normal heterodimer
formation and surface display. Recently, variant LAD I syndromes have
been identified (80, 81).7
Each of these subjects had clinical features consistent with LAD I but,
in contrast to the phenotype outlined above, had normal or only
moderately reduced levels of 2 integrins (40-60% of
control) on the surfaces of circulating leukocytes at the time of
diagnosis. In one of the subjects there were two new mutations of the
chain; one was located in the MIDAS motif of the I-like domain
(81). Phenotypic and sequence characterization of leukocytes from the other two subjects indicates a defect in inside-out signaling. These
rare LAD variants, like variations in structure and signaling of
integrin IIb 3 in the syndrome of
Glanzmann thrombasthenia (82), may yield unique insights that are
relevant both to 2 heterodimers on leukocytes and to the
biology of integrins in general.
 |
ACKNOWLEDGEMENTS |
We thank Takashi Kei Kishimoto and Nancy Hogg
for making unpublished manuscripts available to us, John McDonald for
editorial comments, Michelle Bills and Diana Lim for preparation of the manuscript and figure, and the members of our group and many other colleagues for useful discussions and other contributions.
 |
FOOTNOTES |
*
This minireview will be reprinted
in the 2000 Minireview Compendium, which
will be available in December, 2000. This is the third article of four in the "Integrin
Minireview Series." This work was supported by National Institutes of
Health Grants HL44525, K08 HL03799, CA59548, and P50 HL50153, an Asthma
Research Center funded by the American Lung Association, the Eccles
Program in Human Molecular Biology and Genetics, and the Huntsman
Cancer Foundation.

To whom correspondence should be addressed: Program in Human
Molecular Biology and Genetics, Suite 4220, Eccles Inst. of Human Genetics, University of Utah Health Sciences Center, Salt Lake City, UT
84112. Tel.: 801-585-0727; Fax: 801-585-0701; E-mail: guy.zimmerman@hmbg.utah.edu.
Published, JBC Papers in Press, May 4, 2000, DOI 10.1074/jbc.R000004200
2
The 2 integrins are
comprehensively reviewed in Ref. 1. In the last decade dozens of
reviews and hundreds of primary reports on leukocyte function,
leukocyte integrins, and specific aspects of the biology of integrins
have appeared. We used many that could not be cited because of space
limitations and will provide a list of these on request.
3
The designations for the 2
integrin heterodimers and their individual peptide subunits can be
confusing. The trivial names LFA-1, MAC-1, and GP150,95 antedated the
more recent designations of L 2,
M 2, and X 2,
respectively, and are still often used. M 2 integrin was also earlier called MO-1
and complement receptor 3 (CR3). The CD designations for the individual
subunits are CD11a ( L), CD11b ( M), CD11c
( X), and CD18 ( 2). The D
chain will likely be assigned as CD11d (1).
4
M. Feldhaus, G. A. Zimmerman, and T. M. McIntyre, submitted for publication.
5
PI 3-kinases, PKC, and integrins are reviewed in
Kolanus and Seed (86).
6
M. Bunting, T. M. McIntyre, S. M. Prescott, and
G. A. Zimmerman, unpublished observations.
7
E. S. Harris, A. D. Shigedka, W. Li, R. H. Adams, S. M. Prescott, T. M. McIntyre, G. A. Zimmerman, and D. E. Lorant, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
PMN, polymorphonuclear leukocyte;
ICAM, intercellular adhesion molecule;
MIDAS, metal ion-dependent adhesion site;
PI, phosphatidylinositol;
PKC, protein kinase C;
PH, pleckstrin homology;
FAK, focal adhesion kinase;
LAD I, leukocyte adhesion deficiency type
I.
 |
REFERENCES |
| 1.
|
Kishimoto, T. K.,
Baldwin, E. T.,
and Anderson, D. C.
(1999)
in
Inflammation: Basic Principles and Clinical Correlates
(Gallin, J. I.
, and Snyderman, R., eds), 3rd Ed.
, pp. 537-570, Lippincott Williams and Wilkins, Philadelphia
|
| 2.
|
Lorant, D. E.,
Patel, K. D.,
McIntyre, T. M.,
McEver, R. P.,
Prescott, S. M.,
and Zimmerman, G. A.
(1991)
J. Cell Biol.
115,
223-234
|
| 3.
|
Rainger, G. E.,
Buckley, C.,
Simmons, D. L.,
and Nash, G. B.
(1997)
Curr. Biol.
7,
316-325
|
| 4.
|
Feldhaus, M. J.,
Kessel, J. M.,
Zimmerman, G. A.,
and McIntyre, T. M.
(1998)
J. Immunol.
161,
6280-6287
|
| 5.
|
Campbell, J. J.,
Hendrick, K.,
Zlotnick, A.,
Siani, M. A.,
Thompson, D. A.,
and Butcher, E. C.
(1998)
Science
279,
381-384
|
| 6.
|
Johnston, B.,
Burns, A. R.,
Suematsu, M.,
Issekutz, T. B.,
Woodman, R. C.,
and Kubes, P.
(1999)
J. Clin. Invest.
103,
1269-1276
|
| 7.
|
Krissansen, G. W.,
Elliott, M. J.,
Lucas, C. M.,
Stomski, F. C.,
Berndt, M. C.,
Cheresh, D. A.,
Lopez, A. F.,
and Burns, G. F.
(1990)
J. Biol. Chem.
265,
823-830
|
| 8.
|
Bohnsack, J. F.,
Akiyama, S. K.,
Damsky, C. H.,
Knape, W. A.,
and Zimmerman, G. A.
(1990)
J. Exp. Med.
171,
1221-1237
|
| 9.
|
Kubes, P.,
Niu, X. F.,
Smith, C. W.,
Kehrli, M. E., Jr.,
Reinhardt, P. H.,
and Woodman, R. C.
(1995)
FASEB J.
9,
1103-1111
|
| 10.
|
Hendey, B.,
Lawson, M.,
Marcantonio, E. E.,
and Maxfield, F. R.
(1996)
Blood
87,
2038-2048
|
| 11.
|
Yauch, R. L.,
Berditchevski, F.,
Harler, M. B.,
Reichner, J.,
and Hemler, M. E.
(1998)
Mol. Biol. Cell
9,
2751-2765
|
| 12.
|
Taooka, Y.,
Chen, J.,
Yednock, T.,
and Sheppard, D.
(1999)
J. Cell Biol.
145,
413-420
|
| 13.
|
Danilenko, D. M.,
Rossitto, P. V.,
Van der Vieren, M.,
Le Trong, H.,
McDonough, S. P.,
Affolter, V. K.,
and Moore, P. F.
(1995)
J. Immunol.
155,
35-44
|
| 14.
|
Van der Vieren, M.,
Le Trong, H.,
Wood, C. L.,
Moore, P. F.,
St. John, T.,
Staunton, D. E.,
and Gallatin, W. M.
(1995)
Immunity
3,
683-690
|
| 15.
|
Grayson, M. H.,
Van der Vieren, M.,
Sterbinsky, S. A.,
Gallatin, W. M.,
Hoffman, P. A.,
Staunton, D. E.,
and Bochner, B. S.
(1998)
J. Exp. Med.
188,
2187-2191
|
| 16.
|
Van der Vieren, M.,
Crowe, D. T.,
Hoekstra, D.,
Vazeux, R.,
Hoffman, P. A.,
Grayson, M. H.,
Bochner, B. S.,
Gallatin, W. M.,
and Staunton, D. E.
(1999)
J. Immunol.
163,
1984-1990
|
| 17.
|
Lee, J. O.,
Rieu, P.,
Arnaout, M. A.,
and Liddington, R.
(1995)
Cell
80,
631-638
|
| 18.
|
Goodman, T. G.,
and Bajt, M. L.
(1996)
J. Biol. Chem.
271,
23729-23736
|
| 19.
|
Wong, D. A.,
Davis, E. M.,
LeBeau, M.,
and Springer, T. A.
(1996)
Gene (Amst.)
171,
291-294
|
| 20.
|
Springer, T. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
65-72
|
| 21.
|
Hughes, P. E.,
Diaz-Gonzalez, F.,
Leong, L.,
Wu, C.,
McDonald, J. A.,
Shattil, S. J.,
and Ginsberg, M. H.
(1996)
J. Biol. Chem.
271,
6571-6574
|
| 22.
|
Hughes, B. J.,
Hollers, J. C.,
Crockett-Torabi, E.,
and Smith, C. W.
(1992)
J. Clin. Invest.
90,
1687-1696
|
| 23.
|
Qu, A.,
and Leahy, D. J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10277-10281
|
| 24.
|
Michishita, M.,
Videm, V.,
and Arnaout, M. A.
(1993)
Cell
72,
857-867
|
| 25.
|
Bajt, M. L.,
Goodman, T.,
and McGuire, S. L.
(1995)
J. Biol. Chem.
270,
94-98
|
| 26.
|
Lee, J. O.,
Bankston, L. A.,
Arnaout, M. A.,
and Liddington, R. C.
(1995)
Structure
3,
1333-1340
|
| 27.
|
Li, R.,
Rieu, P.,
Griffith, D. L.,
Scott, D.,
and Amin Arnaout, M.
(1998)
J. Cell Biol.
143,
1523-1534
|
| 28.
|
Loftus, J. C.,
and Liddington, R. C.
(1997)
J. Clin. Invest.
99,
2302-2306
|
| 29.
|
Jones, S. L.,
Knaus, U. G.,
Bokoch, G. M.,
and Brown, E. J.
(1998)
J. Biol. Chem.
273,
10556-10566
|
| 30.
|
Weber, K. S.,
Klickstein, L. B.,
and Weber, C.
(1999)
Mol. Biol. Cell
10,
861-873
|
| 31.
|
Baker, E. K.,
Tozer, E. C.,
Pfaff, M.,
Shattil, S. J.,
Loftus, J. C.,
and Ginsberg, M. H.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1973-1978
|
| 32.
|
Romzek, N. C.,
Harris, E. S.,
Dell, C. L.,
Skronek, J.,
Hasse, E.,
Reynolds, P. J.,
Hunt, S. W., III,
and Shimizu, Y.
(1998)
Mol. Biol. Cell
9,
2715-2727
|
| 33.
|
Laudanna, C.,
Campbell, J. J.,
and Butcher, E. C.
(1996)
Science
271,
981-983
|
| 34.
|
Laudanna, C.,
Campbell, J. J.,
and Butcher, E. C.
(1997)
J. Biol. Chem.
272,
24141-24144
|
| 35.
|
Kolanus, W.,
Nagel, W.,
Schiller, B.,
Zeitlmann, L.,
Godar, S.,
Stockinger, H.,
and Seed, B.
(1996)
Cell
86,
233-242
|
| 36.
|
Lub, M.,
van Vliet, S. J.,
Oomen, S. P.,
Pieters, R. A.,
Robinson, M.,
Figdor, C. G.,
and van Kooyk, Y.
(1997)
Mol. Biol. Cell
8,
719-728
|
| 37.
|
Sadhu, C.,
Masinovsky, B.,
and Staunton, D. E.
(1998)
J. Immunol.
160,
5622-5628
|
| 38.
|
Hibbs, M. L.,
Jakes, S.,
Stacker, S. A.,
Wallace, R. W.,
and Springer, T. A.
(1991)
J. Exp. Med.
174,
1227-1238
|
| 39.
|
Lollo, B. A.,
Chan, K. W.,
Hanson, E. M.,
Moy, V. T.,
and Brian, A. A.
(1993)
J. Biol. Chem.
268,
21693-21700
|
| 40.
|
Petruzzelli, L.,
Maduzia, L.,
and Springer, T. A.
(1998)
J. Immunol.
160,
4208-4216
|
| 41.
|
McDowall, A.,
Leitinger, B.,
Stanley, P.,
Bates, P. A.,
Randi, A. M.,
and Hogg, N.
(1998)
J. Biol. Chem.
273,
27396-27403
|
| 42.
|
van Kooyk, Y.,
Weder, P.,
Heije, K.,
and Figdor, C. G.
(1994)
J. Cell Biol.
124,
1061-1070
|
| 43.
|
Stewart, M. P.,
Cabanas, C.,
and Hogg, N.
(1996)
J. Immunol.
156,
1810-1817
|
| 44.
|
Stewart, M. P.,
McDowall, A.,
and Hogg, N.
(1998)
J. Cell Biol.
140,
699-707
|
| 45.
|
Kucik, D. F.,
Dustin, M. L.,
Miller, J. M.,
and Brown, E. J.
(1996)
J. Clin. Invest.
97,
2139-2144
|
| 46.
|
Krauss, K.,
and Altevogt, P.
(1999)
J. Biol. Chem.
274,
36921-36927
|
| 47.
|
Peter, K.,
and O'Toole, T. E.
(1995)
J. Exp. Med.
181,
315-326
|
| 48.
|
van Kooyk, Y.,
van Vliet, S. J.,
and Figdor, C. G.
(1999)
J. Biol. Chem.
274,
26869-26877
|
| 49.
|
Dustin, M. L.,
Olszowy, M. W.,
Holdorf, A. D.,
Li, J.,
Bromley, S.,
Desai, N.,
Widder, P.,
Rosenberger, F.,
van der Merwe, P. A.,
Allen, P. M.,
and Shaw, A. S.
(1998)
Cell
94,
667-677
|
| 50.
|
Monks, C. R.,
Freiberg, B. A.,
Kupfer, H.,
Sciaky, N.,
and Kupfer, A.
(1998)
Nature
395,
82-86
|
| 51.
|
Lu, C. F.,
and Springer, T. A.
(1997)
J. Immunol.
159,
268-278
|
| 52.
|
Sampath, R.,
Gallagher, P. J.,
and Pavalko, F. M.
(1998)
J. Biol. Chem.
273,
33588-33594
|
| 53.
|
Tominaga, T.,
Sugie, K.,
Hirata, M.,
Morii, N.,
Fukata, J.,
Uchida, A.,
Imura, H.,
and Narumiya, S.
(1993)
J. Cell Biol.
120,
1529-1537
|
| 54.
|
Nagel, W.,
Zeitlmann, L.,
Schilcher, P.,
Geiger, C.,
Kolanus, J.,
and Kolanus, W.
(1998)
J. Biol. Chem.
273,
14853-14861
|
| 55.
|
Nagel, W.,
Schilcher, P.,
Zeitlmann, L.,
and Kolanus, W.
(1998)
Mol. Biol. Cell
9,
1981-1994
|
| 56.
|
Hmama, Z.,
Knutson, K. L.,
Herrera-Velit, P.,
Nandan, D.,
and Reiner, N. E.
(1999)
J. Biol. Chem.
274,
1050-1057
|
| 57.
|
Korthauer, U.,
Nagel, W.,
Davis, E. M.,
Le Beau, M. M.,
Menon, R. S.,
Mitchell, E. O.,
Kozak, C. A.,
Kolanus, W.,
and Bluestone, J. A.
(2000)
J. Immunol.
164,
308-318
|
| 58.
|
Li, R.,
Xie, J.,
Kantor, C.,
Koistinen, V.,
Altieri, D. C.,
Nortamo, P.,
and Gahmberg, C. G.
(1995)
J. Cell Biol.
129,
1143-1153
|
| 59.
|
Jones, S. L.,
Wang, J.,
Turck, C. W.,
and Brown, E. J.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9331-9336
|
| 60.
|
Reinhold, S. L.,
Prescott, S. M.,
Zimmerman, G. A.,
and McIntyre, T. M.
(1990)
FASEB J.
4,
208-214
|
| 61.
|
Wang, G. J.,
Collinge, M.,
Blasi, F.,
Pardi, R.,
and Bender, J. R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6296-6301
|
| 62.
|
Yurochko, A. D.,
Liu, D. Y.,
Eierman, D.,
and Haskill, S.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
9034-9038
|
| 63.
|
Lin, T. H.,
Yurochko, A.,
Kornberg, L.,
Morris, J.,
Walker, J. J.,
Haskill, S.,
and Juliano, R. L.
(1994)
J. Cell Biol.
126,
1585-1593
|
| 64.
|
Couturier, C.,
Haeffner-Cavaillon, N.,
Weiss, L.,
Fischer, E.,
and Kazatchkine, M. D.
(1990)
Eur. J. Immunol.
20,
999-1005
|
| 65.
|
Pardi, R.,
Bender, J. R.,
Dettori, C.,
Giannazza, E.,
and Engleman, E. G.
(1989)
J. Immunol.
143,
3157-3166
|
| 66.
|
Zhou, M. J.,
and Brown, E. J.
(1994)
J. Cell Biol.
125,
1407-1416
|
| 67.
|
Berton, G.,
Fumagalli, L.,
Laudanna, C.,
and Sorio, C.
(1994)
J. Cell Biol.
126,
1111-1121
|
| 68.
|
Schaller, M. D.,
Otey, C. A.,
Hildebrand, J. D.,
and Parsons, J. T.
(1995)
J. Cell Biol.
130,
1181-1187
|
| 69.
|
Hidari, K. I.,
Weyrich, A. S.,
Zimmerman, G. A.,
and McEver, R. P.
(1997)
J. Biol. Chem.
272,
28750-28756
|
| 70.
|
Lin, T. H.,
Rosales, C.,
Mondal, K.,
Bolen, J. B.,
Haskill, S.,
and Juliano, R. L.
(1995)
J. Biol. Chem.
270,
16189-16197
|
| 71.
|
Rojiani, M. V.,
Finlay, B. B.,
Gray, V.,
and Dedhar, S.
(1991)
Biochemistry
30,
9859-9866
|
| 72.
|
Hannigan, G. E.,
Leung-Hagesteijn, C.,
Fitz-Gibbon, L.,
Coppolino, M. G.,
Radeva, G.,
Filmus, J.,
Bell, J. C.,
and Dedhar, S.
(1996)
Nature
379,
91-96
|
| 73.
|
Wilson, R. W.,
Ballantyne, C. M.,
Smith, C. W.,
Montgomery, C.,
Bradley, A.,
O'Brien, W. E.,
and Beaudet, A. L.
(1993)
J. Immunol.
151,
1571-1578
|
| 74.
|
Mizgerd, J. P.,
Kubo, H.,
Kutkoski, G. J.,
Bhagwan, S. D.,
Scharffetter-Kochanek, K.,
Beaudet, A. L.,
and Doerschuk, C. M.
(1997)
J. Exp. Med.
186,
1357-1364
|
| 75.
|
Schmits, R.,
Kundig, T. M.,
Baker, D. M.,
Shumaker, G.,
Simard, J. J.,
Duncan, G.,
Wakeham, A.,
Shahinian, A.,
van der Heiden, A.,
Bachmann, M. F.,
Ohashi, P. S.,
Mak, T. W.,
and Hickstein, D. D.
(1996)
J. Exp. Med.
183,
1415-1426
|
| 76.
|
Coxon, A.,
Rieu, P.,
Barkalow, F. J.,
Askari, S.,
Sharpe, A. H.,
von Andrian, U. H.,
Arnaout, M. A.,
and Mayadas, T. N.
(1996)
Immunity
5,
653-666
|
| 77.
|
Lu, H.,
Smith, C. W.,
Perrard, J.,
Bullard, D.,
Tang, L.,
Shappell, S. B.,
Entman, M. L.,
Beaudet, A. L.,
and Ballantyne, C. M.
(1997)
J. Clin. Invest.
99,
1340-1350
|
| 78.
|
Tang, T.,
Rosenkranz, A.,
Assmann, K. J. M.,
Goodman, M. J.,
Gutierrez-Ramos, J. C.,
Carroll, M. C.,
Cotran, R. S.,
and Mayadas, T. N.
(1997)
J. Exp. Med.
186,
1853-1863
|
| 79.
|
Rosenkranz, A. R.,
Coxon, A.,
Maurer, M.,
Gurish, M. F.,
Austen, K. F.,
Friend, D. S.,
Galli, S. J.,
and Mayadas, T. N.
(1998)
J. Immunol.
161,
6463-6467
|
| 80.
|
Kuijpers, T. W.,
Van Lier, R. A.,
Hamann, D.,
de Boer, M.,
Thung, L. Y.,
Weening, R. S.,
Verhoeven, A. J.,
and Roos, D.
(1997)
J. Clin. Invest.
100,
1725-1733
|
| 81.
|
Hogg, N.,
Stewart, M. P.,
Scarth, S. L.,
Newton, R.,
Shaw, J. M.,
Law, S. K.,
and Klein, N.
(1999)
J. Clin. Invest.
103,
97-106
|
| 82.
|
Wang, R.,
Shattil, S. J.,
Ambruso, D. R.,
and Newman, P. J.
(1997)
J. Clin. Invest.
100,
2393-2403
|
| 83.
|
Woods, A.,
and Couchman, J. R.
(2000)
J. Biol. Chem.
275,
24233-24236
|
| 84.
|
Plow, E. F.,
Haas, T. A.,
Zhang, L.,
Loftus, J.,
and Smith, J. W.
(2000)
J. Biol. Chem.
275,
21785-21788
|
| 85.
|
Calderwood, D. A.,
Shattil, S. J.,
and Ginsberg, M. H.
(2000)
J. Biol. Chem.
275,
22607-22610
|
| 86.
|
Kolanus, W.,
and Seed, B.
(1997)
Curr. Opin. Cell Biol.
9,
725-731
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Md. M. Aziz, S. Ishihara, Y. Mishima, N. Oshima, I. Moriyama, T. Yuki, Y. Kadowaki, M. A. K. Rumi, Y. Amano, and Y. Kinoshita
MFG-E8 Attenuates Intestinal Inflammation in Murine Experimental Colitis by Modulating Osteopontin-Dependent {alpha}v{beta}3 Integrin Signaling
J. Immunol.,
June 1, 2009;
182(11):
7222 - 7232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Glawe, D. R. Patrick, M. Huang, C. D. Sharp, S. C. Barlow, and C. G. Kevil
Genetic Deficiency of Itgb2 or ItgaL Prevents Autoimmune Diabetes Through Distinctly Different Mechanisms in NOD/LtJ Mice
Diabetes,
June 1, 2009;
58(6):
1292 - 1301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. W. S. Kum, S. Lee, G. A. Grassl, R. Bidshahri, K. Hsu, H. J. Ziltener, and B. B. Finlay
Lack of Functional P-Selectin Ligand Exacerbates Salmonella Serovar Typhimurium Infection
J. Immunol.,
May 15, 2009;
182(10):
6550 - 6561.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Tsukuba, M. Yanagawa, K. Okamoto, Y. Okamoto, Y. Yasuda, K. I. Nakayama, T. Kadowaki, and K. Yamamoto
Impaired chemotaxis and cell adhesion due to decrease in several cell-surface receptors in cathepsin E-deficient macrophages
J. Biochem.,
May 1, 2009;
145(5):
565 - 573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Notarangelo and R. Badolato
Leukocyte trafficking in primary immunodeficiencies
J. Leukoc. Biol.,
March 1, 2009;
85(3):
335 - 343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. F. Plow and E. Pluskota
Response to Comment on "Neutrophil Apoptosis: Selective Regulation by Different Ligands of Integrin {alpha}M{beta}2"
J. Immunol.,
December 15, 2008;
181(12):
8187 - 8188.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Pluskota, D. A. Soloviev, D. Szpak, C. Weber, and E. F. Plow
Neutrophil Apoptosis: Selective Regulation by Different Ligands of Integrin {alpha}M{beta}2
J. Immunol.,
September 1, 2008;
181(5):
3609 - 3619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. El Kebir, L. Jozsef, W. Pan, and J. G. Filep
Myeloperoxidase Delays Neutrophil Apoptosis Through CD11b/CD18 Integrins and Prolongs Inflammation
Circ. Res.,
August 15, 2008;
103(4):
352 - 359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-H. Lee, J. E. Prince, M. Rais, F. Kheradmand, C. M. Ballantyne, G. Weitz-Schmidt, C. W. Smith, and D. B. Corry
Developmental Control of Integrin Expression Regulates Th2 Effector Homing
J. Immunol.,
April 1, 2008;
180(7):
4656 - 4667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Miyazaki, M. Bunting, D. M. Stafforini, E. S. Harris, T. M. McIntyre, S. M. Prescott, V. S. Frutuoso, F. C. Amendoeira, D. de Oliveira Nascimento, A. Vieira-de-Abreu, et al.
Integrin {alpha}D 2 Is Dynamically Expressed by Inflamed Macrophages and Alters the Natural History of Lethal Systemic Infections
J. Immunol.,
January 1, 2008;
180(1):
590 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. E. Berndt, M. Zhang, G.-H. Chen, G. B. Huffnagle, and J. Y. Kao
The Role of Dendritic Cells in the Development of Acute Dextran Sulfate Sodium Colitis
J. Immunol.,
November 1, 2007;
179(9):
6255 - 6262.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Casadevall, C. Coronell, A. L. Ramirez-Sarmiento, J. Martinez-Llorens, E. Barreiro, M. Orozco-Levi, J. Gea, and on behalf of the ENIGMA in COPD group
Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients
Eur. Respir. J.,
October 1, 2007;
30(4):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Kodali, P. Wu, P. A. Lahiji, E. J. Brown, and J. J. Maher
ANIT toxicity toward mouse hepatocytes in vivo is mediated primarily by neutrophils via CD18
Am J Physiol Gastrointest Liver Physiol,
August 1, 2006;
291(2):
G355 - G363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Henneke and R. Berner
Interaction of neonatal phagocytes with group B streptococcus: recognition and response.
Infect. Immun.,
June 1, 2006;
74(6):
3085 - 3095.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Goebel, M. Huang, W. C. Davis, M. Jennings, T. J. Siahaan, J. S. Alexander, and C. G. Kevil
VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease
Am J Physiol Gastrointest Liver Physiol,
April 1, 2006;
290(4):
G648 - G654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Liu, M. Zhao, N. Li, L. A. Diaz, and T. N. Mayadas
Differential roles for beta2 integrins in experimental autoimmune bullous pemphigoid
Blood,
February 1, 2006;
107(3):
1063 - 1069.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Elitok, S. V. Brodsky, D. Patschan, T. Orlova, K. M. Lerea, P. Chander, and M. S. Goligorsky
Cyclic arginine-glycine-aspartic acid peptide inhibits macrophage infiltration of the kidney and carotid artery lesions in apo-E-deficient mice
Am J Physiol Renal Physiol,
January 1, 2006;
290(1):
F159 - F166.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Kallapur, T. J. M. Moss, M. Ikegami, R. L. Jasman, J. P. Newnham, and A. H. Jobe
Recruited Inflammatory Cells Mediate Endotoxin-induced Lung Maturation in Preterm Fetal Lambs
Am. J. Respir. Crit. Care Med.,
November 15, 2005;
172(10):
1315 - 1321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Guerau-de-Arellano, J. Alroy, D. Bullard, and B. T. Huber
Aggravated Lyme Carditis in CD11a-/- and CD11c-/- Mice
Infect. Immun.,
November 1, 2005;
73(11):
7637 - 7643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Gopinath, T. C. Ambagala, M. S. Deshpande, R. O. Donis, and S. Srikumaran
Mannheimia (Pasteurella) haemolytica Leukotoxin Binding Domain Lies within Amino Acids 1 to 291 of Bovine CD18
Infect. Immun.,
September 1, 2005;
73(9):
6179 - 6182.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Powner, R. M. Payne, T. R. Pettitt, M. L. Giudici, R. F. Irvine, and M. J. O. Wakelam
Phospholipase D2 stimulates integrin-mediated adhesion via phosphatidylinositol 4-phosphate 5-kinase I{gamma}b
J. Cell Sci.,
July 1, 2005;
118(13):
2975 - 2986.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Guerau-de-Arellano, J. Alroy, and B. T. Huber
{beta}2 Integrins Control the Severity of Murine Lyme Carditis
Infect. Immun.,
June 1, 2005;
73(6):
3242 - 3250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Noti, A. K. Johnson, and J. D. Dillon
The Leukocyte Integrin Gene CD11d Is Repressed by Gut-enriched Kruppel-like Factor 4 in Myeloid Cells
J. Biol. Chem.,
February 4, 2005;
280(5):
3449 - 3457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Yonekawa and J. M. Harlan
Targeting leukocyte integrins in human diseases
J. Leukoc. Biol.,
February 1, 2005;
77(2):
129 - 140.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Solovjov, E. Pluskota, and E. F. Plow
Distinct Roles for the {alpha} and {beta} Subunits in the Functions of Integrin {alpha}M{beta}2
J. Biol. Chem.,
January 14, 2005;
280(2):
1336 - 1345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Lau, H. Mollnau, J. P. Eiserich, B. A. Freeman, A. Daiber, U. M. Gehling, J. Brummer, V. Rudolph, T. Munzel, T. Heitzer, et al.
Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins
PNAS,
January 11, 2005;
102(2):
431 - 436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Huang, K. Matthews, T. J. Siahaan, and C. G. Kevil
{alpha}L-Integrin I domain cyclic peptide antagonist selectively inhibits T cell adhesion to pancreatic islet microvascular endothelium
Am J Physiol Gastrointest Liver Physiol,
January 1, 2005;
288(1):
G67 - G73.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. P. E. M. Spijkers, P. da Costa Martins, E. Westein, C. G. Gahmberg, J. J. Zwaginga, and P. J. Lenting
LDL-receptor-related protein regulates {beta}2-integrin-mediated leukocyte adhesion
Blood,
January 1, 2005;
105(1):
170 - 177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Ren, M. A. McCrory, C. Pass, D. C. Bullard, C. M. Ballantyne, Y. Xu, D. E. Briles, and A. J. Szalai
The Virulence Function of Streptococcus pneumoniae Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor-Mediated Protection
J. Immunol.,
December 15, 2004;
173(12):
7506 - 7512.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Sivalenka and R. Jessberger
SWAP-70 Regulates c-kit-Induced Mast Cell Activation, Cell-Cell Adhesion, and Migration
Mol. Cell. Biol.,
December 1, 2004;
24(23):
10277 - 10288.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Barlow, W. Langston, K. M. Matthews, J. H. Chidlow Jr, and C. G. Kevil
CD18 Deficiency Protects against Multiple Low-Dose Streptozotocin-Induced Diabetes
Am. J. Pathol.,
December 1, 2004;
165(6):
1849 - 1852.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Kanse, R. L. Matz, K. T. Preissner, and K. Peter
Promotion of Leukocyte Adhesion by a Novel Interaction Between Vitronectin and the {beta}2 Integrin Mac-1 ({alpha}M{beta}2, CD11b/CD18)
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2004;
24(12):
2251 - 2256.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. G. Kevil, M. J. Hicks, X. He, J. Zhang, C. M. Ballantyne, C. Raman, T. R. Schoeb, and D. C. Bullard
Loss of LFA-1, but not Mac-1, Protects MRL/MpJ-Faslpr Mice from Autoimmune Disease
Am. J. Pathol.,
August 1, 2004;
165(2):
609 - 616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Noti, A. K. Johnson, and J. D. Dillon
The Zinc Finger Transcription Factor Transforming Growth Factor {beta}-Inducible Early Gene-1 Confers Myeloid-specific Activation of the Leukocyte Integrin CD11d Promoter
J. Biol. Chem.,
June 25, 2004;
279(26):
26948 - 26958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kaminski, C. B. Pohl, C. Sponholz, N. Ma, C. Stamm, B. Vollmar, and G. Steinhoff
Up-Regulation of Endothelial Nitric Oxide Synthase Inhibits Pulmonary Leukocyte Migration Following Lung Ischemia-Reperfusion in Mice
Am. J. Pathol.,
June 1, 2004;
164(6):
2241 - 2249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Sanchez-Martin, N. Sanchez-Sanchez, M. D. Gutierrez-Lopez, A. I. Rojo, M. Vicente-Manzanares, M. J. Perez-Alvarez, P. Sanchez-Mateos, X. R. Bustelo, A. Cuadrado, F. Sanchez-Madrid, et al.
Signaling through the Leukocyte Integrin LFA-1 in T Cells Induces a Transient Activation of Rac-1 That Is Regulated by Vav and PI3K/Akt-1
J. Biol. Chem.,
April 16, 2004;
279(16):
16194 - 16205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. McLeod, A. J. Shum, R. L. Lee, F. Takei, and M. R. Gold
The Rap GTPases Regulate Integrin-mediated Adhesion, Cell Spreading, Actin Polymerization, and Pyk2 Tyrosine Phosphorylation in B Lymphocytes
J. Biol. Chem.,
March 26, 2004;
279(13):
12009 - 12019.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kettritz, M. Choi, S. Rolle, M. Wellner, and F. C. Luft
Integrins and Cytokines Activate Nuclear Transcription Factor-{kappa}B in Human Neutrophils
J. Biol. Chem.,
January 23, 2004;
279(4):
2657 - 2665.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. de Saint-Vis, C. Bouchet, G. Gautier, J. Valladeau, C. Caux, and P. Garrone
Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin
Blood,
December 15, 2003;
102(13):
4431 - 4440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Favre, M. Mancuso, K. Maas, J. W. McLean, P. Baluk, and D. M. McDonald
Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung
Am J Physiol Heart Circ Physiol,
November 1, 2003;
285(5):
H1917 - H1938.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. David, Y. Kacher, U. Specks, and I. Aviram
Interaction of proteinase 3 with CD11b/CD18 ({beta}2integrin) on the cell membrane of human neutrophils
J. Leukoc. Biol.,
October 1, 2003;
74(4):
551 - 557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Giannoni, P. Chiarugi, G. Cozzi, L. Magnelli, M. L. Taddei, T. Fiaschi, F. Buricchi, G. Raugei, and G. Ramponi
Lymphocyte Function-associated Antigen-1-mediated T Cell Adhesion Is Impaired by Low Molecular Weight Phosphotyrosine Phosphatase-dependent Inhibition of FAK Activity
J. Biol. Chem.,
September 19, 2003;
278(38):
36763 - 36776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Adair-Kirk, J. J. Atkinson, T. J. Broekelmann, M. Doi, K. Tryggvason, J. H. Miner, R. P. Mecham, and R. M. Senior
A Site on Laminin {alpha}5, AQARSAASKVKVSMKF, Induces Inflammatory Cell Production of Matrix Metalloproteinase-9 and Chemotaxis
J. Immunol.,
July 1, 2003;
171(1):
398 - 406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Krivacic and A. D. Levine
Extracellular Matrix Conditions T Cells for Adhesion to Tissue Interstitium
J. Immunol.,
May 15, 2003;
170(10):
5034 - 5044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Shen, L. Guo, A. Wallace, J. Fitzner, J. Eisenman, E. Jacobson, and R. S. Johnson
Isolation and Isotope Labeling of Cysteine- and Methionine-containing Tryptic Peptides: Application to the Study of Cell Surface Proteolysis
Mol. Cell. Proteomics,
May 1, 2003;
2(5):
315 - 324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. S. Bansal, S. Vaidya, E. P. Somers, M. Kanuga, D. Shevell, R. Weikel, and P. A. Detmers
Small Molecule Antagonists of Complement Receptor Type 3 Block Adhesion and Adhesion-Dependent Oxidative Burst in Human Polymorphonuclear Leukocytes
J. Pharmacol. Exp. Ther.,
March 1, 2003;
304(3):
1016 - 1024.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Caron
Cellular functions of the Rap1 GTP-binding protein: a pattern emerges
J. Cell Sci.,
February 1, 2003;
116(3):
435 - 440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Heil, T. Ziegelhoeffer, F. Pipp, S. Kostin, S. Martin, M. Clauss, and W. Schaper
Blood monocyte concentration is critical for enhancement of collateral artery growth
Am J Physiol Heart Circ Physiol,
December 1, 2002;
283(6):
H2411 - H2419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fiorini, W. Vermi, F. Facchetti, D. Moratto, G. Alessandri, L. Notarangelo, A. Caruso, P. Grigolato, A. G. Ugazio, L. D. Notarangelo, et al.
Defective migration of monocyte-derived dendritic cells in LAD-1 immunodeficiency
J. Leukoc. Biol.,
October 1, 2002;
72(4):
650 - 656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. E. DesJardin, T. M. Kaufman, B. Potts, B. Kutzbach, H. Yi, and L. S. Schlesinger
Mycobacterium tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, Fc{gamma}RII and the mannose receptor
Microbiology,
October 1, 2002;
148(10):
3161 - 3171.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Lindstedt, B. Johansson-Lindbom, and C. A. K. Borrebaeck
Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators
Int. Immunol.,
October 1, 2002;
14(10):
1203 - 1213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Myou, X. Zhu, E. Boetticher, S. Myo, A. Meliton, A. Lambertino, N. M. Munoz, and A. R. Leff
Blockade of Focal Clustering and Active Conformation in {beta}2-Integrin-Mediated Adhesion of Eosinophils to Intercellular Adhesion Molecule-1 Caused by Transduction of HIV TAT-Dominant Negative Ras
J. Immunol.,
September 1, 2002;
169(5):
2670 - 2676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhao, L. Yue, D. Gu, and T. Mazzone
Regulation of Macrophage ApoE Expression and Processing by Extracellular Matrix
J. Biol. Chem.,
August 9, 2002;
277(33):
29477 - 29483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-T. Lu, P.-G. Chen, and S. F. Liu
Time course of lung ischemia-reperfusion-induced ICAM-1 expression and its role in ischemia-reperfusion lung injury
J Appl Physiol,
August 1, 2002;
93(2):
620 - 628.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Monick, L. Powers, N. Butler, T. Yarovinsky, and G. W. Hunninghake
Interaction of matrix with integrin receptors is required for optimal LPS-induced MAP kinase activation
Am J Physiol Lung Cell Mol Physiol,
August 1, 2002;
283(2):
L390 - L402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Tasaka, S. E. Richer, J. P. Mizgerd, and C. M. Doerschuk
Very Late Antigen-4 in CD18-Independent Neutrophil Emigration during Acute Bacterial Pneumonia in Mice
Am. J. Respir. Crit. Care Med.,
July 1, 2002;
166(1):
53 - 60.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Schober, N. Chen, T. M. Grzeszkiewicz, I. Jovanovic, E. E. Emeson, T. P. Ugarova, R. D. Ye, L. F. Lau, and S. C.-T. Lam
Identification of integrin alpha Mbeta 2 as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions
Blood,
May 29, 2002;
99(12):
4457 - 4465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. A. Ustinov and E. F. Plow
Delineation of the Key Amino Acids Involved in Neutrophil Inhibitory Factor Binding to the I-domain Supports a Mosaic Model for the Capacity of Integrin alpha Mbeta 2 to Recognize Multiple Ligands
J. Biol. Chem.,
May 17, 2002;
277(21):
18769 - 18776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Rodriguez-Fernandez, L. Sanchez-Martin, C. A. de Frutos, D. Sancho, M. Robinson, F. Sanchez-Madrid, and C. Cabanas
LFA-1 integrin and the microtubular cytoskeleton are involved in the Ca2+-mediated regulation of the activity of the tyrosine kinase PYK2 in T cells
J. Leukoc. Biol.,
March 1, 2002;
71(3):
520 - 530.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kamata, K. K. Tieu, T. Tarui, W. Puzon-McLaughlin, N. Hogg, and Y. Takada
The Role of the CPNKEKEC Sequence in the {beta}2 Subunit I Domain in Regulation of Integrin {alpha}L{beta}2 (LFA-1)
J. Immunol.,
March 1, 2002;
168(5):
2296 - 2301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Leitinger and N. Hogg
The involvement of lipid rafts in the regulation of integrin function
J. Cell Sci.,
January 3, 2002;
115(5):
963 - 972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Wang, X.-F. Zhang, and J. E. Groopman
Stimulation of beta 1 Integrin Induces Tyrosine Phosphorylation of Vascular Endothelial Growth Factor Receptor-3 and Modulates Cell Migration
J. Biol. Chem.,
November 2, 2001;
276(45):
41950 - 41957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ruiz, C.-Y. Liu, Q.-H. Sun, M. Sigaud-Fiks, E. Fressinaud, J.-Y. Muller, P. Nurden, A. T. Nurden, P. J. Newman, and N. Valentin
A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa ({alpha}IIb{beta}3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype
Blood,
October 15, 2001;
98(8):
2432 - 2441.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Drbal, P. Angelisova, I. Hilgert, J. Cerny, P. Novak, and V. Horejsi
A proteolytically truncated form of free CD18, the common chain of leukocyte integrins, as a novel marker of activated myeloid cells
Blood,
September 1, 2001;
98(5):
1561 - 1566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Hogg and B. Leitinger
Shape and shift changes related to the function of leukocyte integrins LFA-1 and Mac-1
J. Leukoc. Biol.,
June 1, 2001;
69(6):
893 - 898.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. K BHATIA and D. O HASKARD
Markers of inflammation in unstable angina
Heart,
June 1, 2001;
85(6):
603 - 604.
[Full Text]
|
 |
|

|
 |

|
 |
 
C. B. Forsyth, D. A. Solovjov, T. P. Ugarova, and E. F. Plow
Integrin {alpha}M{beta}2-mediated Cell Migration to Fibrinogen and Its Recognition Peptides
J. Exp. Med.,
May 14, 2001;
193(10):
1123 - 1134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Harris, A. O. Shigeoka, W. Li, R. H. Adams, S. M. Prescott, T. M. McIntyre, G. A. Zimmerman, and D. E. Lorant
A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by {beta}1 and {beta}2 integrins
Blood,
February 1, 2001;
97(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Korade-Mirnics and S. J. Corey
Src kinase-mediated signaling in leukocytes
J. Leukoc. Biol.,
November 1, 2000;
68(5):
603 - 613.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. L. Rodriguez-Fernandez, L. Sanchez-Martin, M. Rey, M. Vicente-Manzanares, S. Narumiya, J. Teixido, F. Sanchez-Madrid, and C. Cabanas
Rho and Rho-associated Kinase Modulate the Tyrosine Kinase PYK2 in T-cells through Regulation of the Activity of the Integrin LFA-1
J. Biol. Chem.,
October 26, 2001;
276(44):
40518 - 40527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. C. Bridges, P. H. Tani, K. R. Hanson, C. M. Roberts, M. B. Judkins, and R. D. Bowditch
The Lymphocyte Metalloprotease MDC-L (ADAM 28) Is a Ligand for the Integrin alpha 4beta 1
J. Biol. Chem.,
January 25, 2002;
277(5):
3784 - 3792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Woods and J. R. Couchman
Integrin Modulation by Lateral Association
J. Biol. Chem.,
August 4, 2000;
275(32):
24233 - 24236.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. F. Plow, T. A. Haas, L. Zhang, J. Loftus, and J. W. Smith
Ligand Binding to Integrins
J. Biol. Chem.,
July 14, 2000;
275(29):
21785 - 21788.
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|